Literature DB >> 23768729

Exacerbation of experimental autoimmune encephalomyelitis by passive transfer of IgG antibodies from a multiple sclerosis patient responsive to immunoadsorption.

Rosetta Pedotti1, Silvia Musio, Stefano Scabeni, Cinthia Farina, Pietro Luigi Poliani, Emanuela Colombo, Massimo Costanza, Angela Berzi, Fabrizio Castellucci, Emilio Ciusani, Paolo Confalonieri, Bernhard Hemmer, Renato Mantegazza, Carlo Antozzi.   

Abstract

The pathogenic role of antibodies in multiple sclerosis (MS) is still controversial. We transferred to mice with experimental autoimmune encephalomyelitis (EAE), animal model of MS, IgG antibodies purified from a MS patient presenting a dramatic clinical improvement during relapse after selective IgG removal with immunoadsorption. Passive transfer of patient's IgG exacerbated motor paralysis and increased mouse central nervous system (CNS) inflammation and demyelination. Binding of patient's IgG was demonstrated in mouse CNS, with a diffuse staining of white matter oligodendrocytes. These data support a growing body of evidence that antibodies can play an important role in the pathobiology of MS.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antibodies; Demyelination; EAE; Experimental autoimmune encephalomyelitis; Immunoadsorption; LNCs; MS; Multiple sclerosis; PBS; PLP; Plasma exchange; T helper; TPE; Th; experimental autoimmune encephalomyelitis; lymph node cells; multiple sclerosis; myelin proteolipid protein; phosphate buffer saline; plasma exchange

Mesh:

Substances:

Year:  2013        PMID: 23768729     DOI: 10.1016/j.jneuroim.2013.05.010

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  7 in total

1.  CD98 is a potential target for ablating B cell clonal expansion and autoantibody in multiple sclerosis.

Authors:  Joseph M Cantor
Journal:  J Neuroimmunol       Date:  2014-06-26       Impact factor: 3.478

Review 2.  B cells in MS and NMO: pathogenesis and therapy.

Authors:  Markus Krumbholz; Edgar Meinl
Journal:  Semin Immunopathol       Date:  2014-05-16       Impact factor: 9.623

3.  Neurofilament light as an immune target for pathogenic antibodies.

Authors:  Fabiola Puentes; Baukje J van der Star; Stephanie D Boomkamp; Markus Kipp; Louis Boon; Isabel Bosca; Joel Raffel; Sharmilee Gnanapavan; Paul van der Valk; Jodie Stephenson; Susan C Barnett; David Baker; Sandra Amor
Journal:  Immunology       Date:  2017-08-11       Impact factor: 7.397

4.  Perturbed Microbiota/Immune Homeostasis in Multiple Sclerosis.

Authors:  Delphine Sterlin; Martin Larsen; Jehane Fadlallah; Christophe Parizot; Marina Vignes; Gaëlle Autaa; Karim Dorgham; Catherine Juste; Patricia Lepage; Jennifer Aboab; Savine Vicart; Elisabeth Maillart; Olivier Gout; Catherine Lubetzki; Romain Deschamps; Caroline Papeix; Guy Gorochov
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-05-11

Review 5.  Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis.

Authors:  David Baker; Monica Marta; Gareth Pryce; Gavin Giovannoni; Klaus Schmierer
Journal:  EBioMedicine       Date:  2017-01-31       Impact factor: 8.143

6.  Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses.

Authors:  Steffen Pfeuffer; Leoni Rolfes; Heinz Wiendl; Sven G Meuth; Timo Wirth; Falk Steffen; Marc Pawlitzki; Andreas Schulte-Mecklenbeck; Catharina C Gross; Marcus Brand; Stefan Bittner; Tobias Ruck; Luisa Klotz
Journal:  J Neuroinflammation       Date:  2022-09-07       Impact factor: 9.587

7.  Dramatic recovery of steroid-refractory relapsed multiple sclerosis following Fingolimod discontinuation using selective immune adsorption.

Authors:  Roberto De Masi; Salvatore Accoto; Stefania Orlando; Vincenzo De Blasi; Sergio Pasca; Rocco Scarpello; Leo Spagnolo; Adele Idolo; Antonella De Donno
Journal:  BMC Neurol       Date:  2015-07-31       Impact factor: 2.474

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.